Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promising Phase III Data For Roche/Ipsen's Taspoglutide Heats Up GLP-1 Race

This article was originally published in The Pink Sheet Daily

Executive Summary

Once-weekly human GLP-1 analog taspoglutide shows superior HbA1c reduction to Byetta - and may soon catch Novo's liraglutide.

You may also be interested in...

Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data

Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.

Novo Disappoints With No Liraglutide News, But Growth Is Strong

Novo delivered strong first-half results, but provided little further clarity on liraglutide's progress at FDA.

The Only Way Is Nasdaq – Part Two

It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts